Merck KGaA Discontinues Phase 2 Trial of Berzosertib in Combination With Topotecan
03 Juin 2022 - 4:21PM
Dow Jones News
By Pierre Bertrand
Merck KGaA said Friday that it has discontinued a Phase 2 trial
for berzosertib in combination with topotecan in patients with
relapsed, platinum-resistant small-cell lung cancer.
The German pharmaceuticals and chemicals company said that,
following an interim analysis, the study was discontinued due to
low probability of meeting the pre-defined objective of the
trial.
"SCLC remains a difficult-to-treat disease, with minimal
advances in the past 20 years," Merck said, adding that it will
continue external studies exploring berzosertib in additional
combinations and clinical settings.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
June 03, 2022 10:06 ET (14:06 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Merck KGaA (PK) (USOTC:MKKGY)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Merck KGaA (PK) (OTCMarkets): 0 recent articles
Plus d'articles sur Merck KGaA (PK)